Fujifilm Biotechnologies has marked a significant milestone with the expansion of its operations in Teesside, UK. This development not only enhances the company’s manufacturing capabilities but also reinforces its commitment to biomanufacturing excellence. With an investment of approximately £400 million from Fujifilm Corporation, the site will house the largest single-use biopharmaceutical CDMO facility in the UK.
New Manufacturing Facility
The newly expanded site will feature advanced single-use bioreactors, including 2,000 L and 5,000 L units, ultimately achieving a total capacity of up to 19,000 L. This facility, covering 110,000 square feet, is set to become operational in the first half of 2026. It is designed to cater to small and mid-scale antibody manufacturing while remaining adaptable to future customer needs.
Bioprocess Innovation Centre UK
In conjunction with the manufacturing facility, the Bioprocess Innovation Centre UK (BIC UK) will open its doors. This state-of-the-art laboratory will focus on high-throughput and continuous process development, positioning itself as a global hub for biomanufacturing innovation. With over 102,200 square feet dedicated to laboratory space, this center effectively doubles the campus’s existing capabilities.
Enhancing Supply Chain Agility
The recent investments in both the manufacturing site and the innovation center are poised to enhance the supply chain agility of Fujifilm Biotechnologies’ global network. By expanding its capacity to develop and produce complex medicines, the company aims to address critical health issues such as cancer, neurodegenerative diseases, and rare disorders. The strategic implementation of the kojoX modular approach to biomanufacturing is central to this initiative, harmonizing technology and equipment across its facilities.
Commitment to Sustainability
In alignment with Fujifilm Holdings Corporation’s sustainability goals, the new manufacturing facility will operate entirely on electricity, maximizing the use of renewable energy. All production processes that traditionally relied on gas will transition to electric power, with a target of achieving 100% renewable electricity by 2030. This commitment reflects a broader industry trend towards sustainable practices in biomanufacturing.
Strengthening Partnerships and Community
The expansion celebration featured notable attendees, including Fujifilm’s global leadership and local public officials, emphasizing the importance of collaboration. Fujifilm Biotechnologies aims to support its partners from process development to early clinical manufacturing. By facilitating low-volume therapies for ultra-rare diseases and commercial biologics all under one roof, the company is enhancing its service offerings in the biopharmaceutical sector.
Educational Collaborations
Fujifilm Biotechnologies is also dedicated to nurturing future talent in the life sciences. Through partnerships with institutions such as the University of Edinburgh, the University of Manchester, and the University of York, the company is playing a vital role in developing skills in STEM and advanced manufacturing. This initiative is designed to support the life sciences ecosystem and cultivate the next generation of specialists.
Conclusion
The expansion of Fujifilm Biotechnologies in the UK signifies a transformative step in biomanufacturing and process development. By combining state-of-the-art facilities with a commitment to sustainability and community engagement, Fujifilm is positioning itself as a leader in the global biotechnology landscape. This strategic investment not only enhances its manufacturing capabilities but also ensures a reliable supply of innovative medicines for patients worldwide.
- Key Takeaways:
- Fujifilm’s Teesside expansion includes the UK’s largest single-use biopharmaceutical facility.
- The Bioprocess Innovation Centre will foster global biomanufacturing innovation.
- Sustainability initiatives aim for 100% renewable electricity by 2030.
- Strong educational partnerships support future talent in the life sciences sector.
- The expansion enhances the agility of Fujifilm’s global supply chain.
Read more → www.pharmabiz.com